Group 1 - Matrix Co., Ltd. announced that its wholly-owned subsidiary, Anke Technology, introduced a strategic investor, Shenzhen Jifu New Industry Venture Capital Fund, which invested 5 million yuan for a 10% stake [1] - Heng Rui Medicine received approval from the National Medical Products Administration for its Eicosapentaenoic Acid Ethyl Ester Soft Capsule, aimed at reducing triglyceride levels in patients with severe hypertriglyceridemia [1] - Mo Gao Co., Ltd. announced the resignation of its Vice President Jin Baoshan due to job transfer [1] Group 2 - Yao Wang Technology decided to terminate two fundraising projects and will permanently supplement the remaining funds into working capital [2] - Minhe Livestock reported sales of 25.53 million chicklings in August, generating revenue of 86.41 million yuan, with year-on-year growth of 27.60% [2] - Sichuan Jinding announced the resignation of its Director and General Manager Xiong Jifeng due to personal reasons [3] Group 3 - Taiji Group received approval for clinical trials of its Semaglutide Injection, aimed at blood sugar control in type 2 diabetes patients [5] - Jieput announced plans to increase capital in its affiliate, Suidong Intelligent Technology, with an investment of 5 million yuan for a 5% stake [7] - GeLing Deep Vision's controlling shareholders committed not to reduce their shareholdings for six months starting from September 17, 2025 [8] Group 4 - Huafeng Superfiber reported the resignation of its Vice President Liu Cong due to personal reasons [9] - Xiaoming Co., Ltd. reported sales revenue of 79.90 million yuan from chicken products in August, with year-on-year growth of 11.73% [11] - Lion Head Co., Ltd. announced that its application for issuing shares and cash to acquire assets has been accepted by the Shanghai Stock Exchange [12] Group 5 - Jinlong Automobile reported a bus sales volume of 4,074 units in August, a year-on-year increase of 23.6% [43] - Metro Design signed a contract for the Ho Chi Minh City urban rail transit project in Vietnam, with a total amount of 1.754 trillion VND [45] - North New Road and Bridge announced winning a mining construction project worth 504 million yuan [28]

Core Viewpoint - Taiji Group's subsidiary Fuling Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection for type 2 diabetes [1] Group 1: Company Developments - Fuling Pharmaceutical, a wholly-owned subsidiary of Taiji Group, has been granted a Clinical Trial Approval Notice for Semaglutide injection [1] - The clinical trials will focus on the indication of type 2 diabetes, specifically for blood sugar control in adult patients [1] - The total research and development investment in this project amounts to approximately 44.1834 million yuan [1] Group 2: Product Information - Semaglutide injection is classified as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist [1] - It is intended for use in adult patients with type 2 diabetes to manage blood sugar levels and reduce the risk of major cardiovascular adverse events in those with cardiovascular disease [1]

Core Viewpoint - Taiji Group's subsidiary has received approval for clinical trials of Semaglutide injection, indicating a significant step in diabetes treatment and weight management [1] Company Summary - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Semaglutide injection [1] - Semaglutide is a long-acting GLP-1 receptor agonist that stimulates insulin production, suppresses glucagon secretion, and reduces appetite and food intake [1] Industry Summary - Semaglutide plays a crucial role in the treatment of type 2 diabetes and assists in weight management, highlighting its importance in the pharmaceutical industry [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-071 重庆太极实业（集团）股份有限公司 关于获得司美格鲁肽注射液药物临床试 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司） 全资子公司太极集团重庆涪陵制药厂有限公司（以下简称：涪陵制药 厂）收到国家药品监督管理局关于司美格鲁肽注射液的《药物临床试 验批准通知书》，现将相关情况公告如下： 一、药物基本情况 药品名称：司美格鲁肽注射液 剂型：注射剂 申请事项：境内生产药品注册临床试验 本次涪陵制药厂获批临床的适应症为适用于成人 2 型糖尿病患 者的血糖控制：在饮食控制和运动基础上，接受二甲双胍和/或磺脲 类药物治疗血糖仍控制不佳的成人 2 型糖尿病患者；适用于降低伴有 1 心血管疾病的 2 型糖尿病成人患者的主要心血管不良事件（心血管死 亡、非致死性心肌梗死或非致死性卒中）风险。 截至本公告日，经查询国家药品监督管理局数据库，国内仅有原 研企业诺和诺德（Novo Nordisk In ...

Core Viewpoint - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received approval from the National Medical Products Administration for the clinical trial of Semaglutide injection for type 2 diabetes, indicating progress in the company's drug development pipeline [1] Group 1 - The clinical trial application for Semaglutide injection was accepted on July 4, 2025, and meets the requirements for drug registration [1] - The company has invested approximately RMB 44.1834 million in the research and development of this project to date [1]

Core Viewpoint - Taiji Group's subsidiary, Fuling Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection, which is significant for treating type 2 diabetes and weight management [1] Group 1: Company Developments - Fuling Pharmaceutical has been granted a clinical trial approval for Semaglutide injection, a GLP-1 receptor agonist [1] - The approved indication is for blood sugar control in adult patients with type 2 diabetes who have inadequate control despite treatment with metformin and/or sulfonylureas [1] - The drug is also indicated for reducing the risk of major cardiovascular adverse events in adult patients with type 2 diabetes and cardiovascular disease [1]

Core Viewpoint - Taiji Group's subsidiary, Chongqing Fuling Pharmaceutical Factory, has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection for type 2 diabetes treatment [1] Group 1: Clinical Trial Approval - The approved clinical trial is aimed at adult patients with type 2 diabetes for blood sugar control [1] - The indication is for adults whose blood sugar remains uncontrolled despite treatment with Metformin and/or Sulfonylureas [1] - The trial also targets reducing the risk of major cardiovascular adverse events in adults with type 2 diabetes and cardiovascular diseases [1]

每经AI快讯，9月9日，太极集团（600129）(600129.SH)公告称，全资子公司涪陵制药厂收到国家药品 监督管理局关于司美格鲁肽注射液的《药物临床试验批准通知书》，同意开展2型糖尿病适应症的临床 试验。司美格鲁肽注射液是一种长效人胰高血糖素样肽-1(GLP-1)受体激动剂，适用于成人2型糖尿病患 者的血糖控制以及降低伴有2心血管疾病的2型糖尿病成人患者的主要心血管不良事件风险。公司在该项 目累计研发投入约4418.34万元。 ...

9月9日，太极集团盘中下跌2.02%，截至13:32，报21.84元/股，成交1.96亿元，换手率1.60%，总市值 121.62亿元。 资金流向方面，主力资金净流出3238.84万元，特大单买入110.00万元，占比0.56%，卖出1546.41万元， 占比7.87%；大单买入3209.17万元，占比16.34%，卖出5011.60万元，占比25.51%。 太极集团今年以来股价跌11.65%，近5个交易日跌1.53%，近20日跌7.93%，近60日涨2.01%。 资料显示，重庆太极实业(集团)股份有限公司位于重庆市渝北区恒山东路18号，成立日期1979年11月26 日，上市日期1997年11月18日，公司主营业务涉及主要从事中成药、西药、保健品加工、销售,医疗器 械销售等业务。主营业务收入构成为：医药商业60.23%，医药工业52.62%，中药材资源8.87%，大健康 及国际1.69%，服务业及其他0.12%。 截至6月30日，太极集团股东户数5.41万，较上期减少8.15%；人均流通股10296股，较上期增加8.87%。 2025年1月-6月，太极集团实现营业收入56.58亿元，同比减少27.63%；归母 ...

Core Viewpoint - Taiji Group announced the lifting of the freeze on certain bank accounts of the company and its subsidiary, Southwest Pharmaceutical Co., Ltd., which had been frozen due to a drug sales contract dispute [1] Group 1: Financial Impact - The total amount frozen was 62,921,183.15 yuan, with 20 million yuan specifically related to the dispute with Hangzhou Yueming Pharmaceutical Technology Co., Ltd. [1] - The freezing of bank accounts did not have a significant impact on the company's main operations during the period [1] Group 2: Operational Implications - The restoration of the bank accounts to normal use is beneficial for the overall fund transfer and utilization of the company [1] - This development ensures the normal operation of the company's management activities [1]